Bill 59 adds a new provision to the Health Protection and Promotion Act that requires the Government of Ontario to implement the recommendations in the Rare Diseases Working Group Report (March 10, 2017) and to publish progress updates online every six months until implementation is complete. The updates must identify which recommendations have been implemented and describe steps being taken on the remainder.
The measure converts a previously dormant working‑group report into a statutory obligation and creates a recurring transparency requirement. It stops short of prescribing timelines for individual recommendations, allocating funds, or creating penalties for non‑compliance — so practical change will depend on how the government interprets “implement” and deploys resources to follow through.
At a Glance
What It Does
The bill inserts a new section into the Health Protection and Promotion Act directing the province to carry out the recommendations of the 2017 Rare Diseases Working Group Report and to publish a status update online six months after the provision comes into force and every six months thereafter until all recommendations are implemented. The reporting must state which recommendations are done and what remains to be done.
Who It Affects
Primary actors are the Ministry of Health and Ontario’s system planners (e.g., Ontario Health), which must coordinate implementation and produce biannual website updates. People with rare diseases, patient advocacy organizations, clinicians and researchers will be the principal external stakeholders tracking progress.
Why It Matters
The bill turns an advisory report into a legal obligation to act and creates a sustained transparency mechanism that can be used for public and stakeholder accountability. However, it does not create funding streams, measurable targets, or enforcement tools, so the law's practical effect will depend on executive choices and budget decisions.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Bill 59 amends Ontario’s Health Protection and Promotion Act by adding a short, focused obligation: the government must implement the recommendations from the Rare Diseases Working Group Report dated March 10, 2017. The statute does not restate those recommendations or prioritize among them; it simply imposes a duty on the provincial government to carry them out.
That duty is phrased using mandatory language but paired with an implementation trigger — “as soon as is practicable” — which gives the executive discretion over timing and sequencing.
Alongside the implementation duty, the bill creates a recurring transparency obligation. Starting six months after the new section comes into force and at six‑month intervals thereafter, the government must publish a progress update on a Government of Ontario website.
The updates must identify recommendations already implemented and explain steps being taken on outstanding items. The content and format of those updates are not specified beyond that requirement.The law comes into force on the day it receives Royal Assent, so the first six‑month reporting clock begins immediately upon proclamation.
Importantly, the bill does not include any funding provision, deadlines for individual recommendations, penalties for non‑compliance, or a designated lead agency in the text. That means practical implementation will require internal directions, inter‑agency coordination, and possible budget decisions outside the statute.
For stakeholders, the key outcome is greater transparency and a formal lever to press for action; for the government, the statute creates an ongoing reporting obligation that will structure communications and, potentially, priority setting.Because the bill does not specify how to measure when a recommendation is “implemented,” the requirement invites interpretive choices. The government can meet the letter of the statute by publishing substantive plans and making measurable changes, or it can produce high‑level updates that document incremental steps.
That ambiguity affects how patient groups, providers, and funders will evaluate progress and determine whether further legislative or legal remedies are needed.
The Five Things You Need to Know
The bill inserts section 20.1 into the Health Protection and Promotion Act, directing the provincial government to implement the March 10, 2017 Rare Diseases Working Group Report.
It requires the government to post an update on a Government of Ontario website six months after the section comes into force and every six months thereafter until all recommendations are implemented.
Each required update must identify which recommendations have been implemented and set out the steps being taken to implement any remaining recommendations.
The Act comes into force on Royal Assent but uses the phrase “as soon as is practicable,” giving the executive flexible timing and no statutory schedule for individual recommendations.
The bill contains no funding allocation, no enforcement mechanism or sanctions for non‑implementation, and does not designate a statutory lead agency or measurable implementation standards.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Mandatory duty to implement the 2017 report
This subsection creates the core obligation: the Government of Ontario must implement the recommendations of the Rare Diseases Working Group Report (March 10, 2017). The provision uses mandatory wording but couples it with “as soon as is practicable,” which leaves sequencing, prioritization, and timing to executive discretion. The text does not define “implement” or identify which ministry or body is responsible, so the Ministry of Health will need to issue internal directions or inter‑agency agreements to convert the statutory duty into operational work.
Six‑month public reporting requirement
This subsection requires recurring online reporting: the government must publish an update on a Government of Ontario website six months after the section comes into force and every six months until all recommendations are implemented. The bill prescribes the cadence and minimum content (which recommendations are implemented and what steps remain) but says nothing about format, supporting data, performance metrics, or independent review. Administratively, the obligation imposes a regular communications and record‑keeping task on government staff and creates a public accountability tool for stakeholders.
Effective on Royal Assent
This short provision makes the Act effective on the day it receives Royal Assent. That timing starts the six‑month clock for the first mandated update immediately after proclamation, rather than upon a later regulatory or administrative action.
Naming the law
The short title is the Rare Disease Strategy Act, 2025. The name signals legislative attention to rare‑disease policy but does not itself create any additional duties beyond those set out in the inserted section.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People with rare diseases and their families — the statute establishes a sustained public record of provincial action (or inaction), giving patient communities a formal accountability mechanism to track progress and press for specific service, coverage, or system changes.
- Patient advocacy organizations — mandated updates create predictable advocacy moments and documentary evidence to support campaigns, funding requests, and political pressure.
- Clinicians and researchers focused on rare diseases — a government commitment clarifies policy intent and can catalyze coordination, data sharing, and potential long‑term planning across the health system.
Who Bears the Cost
- Ministry of Health and Ontario Health — responsible for coordinating implementation and producing biannual reports, requiring staff time, project management, and likely internal reallocation of priorities.
- Treasury/Provincial budget holders — if substantive implementation requires new programs, drugs, or infrastructure, Treasury will absorb or allocate the necessary funding, though the bill does not mandate such appropriations.
- Hospitals, specialty clinics and regional service planners — operational changes to deliver any implemented recommendations may increase workload or require service redesign (for example, new referral pathways or data collection) without guaranteed provincial compensation.
Key Issues
The Core Tension
The bill aims to convert a long‑standing advisory report into a binding obligation and to force transparency, but it stops short of allocating resources, deadlines, or enforcement; the central tension is between establishing public accountability through reporting and leaving the substantive, costly work of implementation to discretionary executive decisions.
The bill creates a clear transparency obligation but leaves critical choices to the executive branch. “As soon as is practicable” and the absence of definitional or measurement rules for what counts as implementation mean the government can control both pace and the narrative. That opens the door to two risks: either meaningful program change that improves care for people with rare diseases, or a minimal compliance approach in which the government publishes periodic, high‑level updates while substantive gaps persist.
Because the statute omits funding, timelines for individual recommendations, and enforcement mechanisms, implementation depends on ordinary budgetary and administrative processes. Stakeholders who want durable change will need to push for concrete implementation plans, line‑item funding, and measurable outcomes.
Legally, the lack of sanctions reduces avenues for judicial enforcement; affected parties could seek review of the administrative record, but courts are likely to defer to executive judgments about resource allocation unless there is unlawful procedure or bad faith. Finally, the bill does not specify integration with federal programs, drug funding frameworks, or private insurers—areas where many rare‑disease issues play out—leaving unresolved how provincial implementation will interact with these external levers.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.